Pharmaceutics | Free Full-Text | Pharmacokinetics of a Fixed-Dose Combination Product of Dapagliflozin and Linagliptin and Its Comparison with Co-Administration of Individual Tablets in Healthy Humans
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Dose-response effect of dapagliflozin on day 7 24-hours urinary glucose... | Download Scientific Diagram
Dapagliflozin - wikidoc
Geometric mean AUC and C max from PBPK model simulations compared with... | Download Scientific Diagram
Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus o | IJNRD
Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State - ScienceDirect
Pharmacokinetic parameters of DWP16001, dapagliflozin, and... | Download Scientific Diagram
Forxiga Full Prescribing Information, Dosage & Side Effects | MIMS Philippines
Xigduo XR Dosage/Direction for Use | MIMS Malaysia
Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study | BMJ Open Diabetes
Dapagliflozin - wikidoc
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial - The
JPM | Free Full-Text | Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
Forxiga Full Prescribing Information, Dosage & Side Effects | MIMS Philippines
Dapagliflozin - wikidoc
Dapagliflozin for the Treatment of Type 2 Diabetes | Semantic Scholar
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment | Federal Practitioner
In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans | Drug Metabolism & Disposition